sponsored
PatientsVille.com Logo

PatientsVille

Advair Medical Research Studies

Up-to-date List of Advair Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Advair Medical Research Studies

Rank Status Study
1 Unknown  Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)
Condition: Asthma
Interventions: Drug: Advair HFA MDI 115/21;   Drug: Symbicort 160/4.5 pMDI
Outcome Measures: Integrated low frequency reactance improvement after initial dosing;   Frequency-dependence of Resistance (R5-R20) after initial dosing;   Model-derived estimates of Large and Small Airway Resistance and Compliance, and their changes after initial dosing
2 Recruiting Dose-Response of Salmeterol in Children
Condition: Asthma
Interventions: Drug: Advair Diskus100/50 µg;   Drug: Flovent Diskus 100 µg;   Drug: Methacholine Chloride;   Drug: Albuterol
Outcome Measures: response to methacholine after administration of salmeterol;   total resistance (R5);   large airway resistance (R20);   small airway resistance (R5-R20);   area of reactance plot (AX area)
3 Unknown  Comparing Fluticasone-Salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep
Condition: COPD
Interventions: Drug: fluticasone/salmeterol 250/50;   Drug: placebo
Outcome Measures: The aim of this study is to determine the effect of fluticasone/salmeterol on sleep quality in patients with COPD and to compare efficacy of Advair 250 compared to placebo on sleep.;   daytime somnolence
4 Recruiting 6-month Safety and Benefit Study of Advair in Children 4-11 Years Old
Condition: Asthma
Interventions: Drug: Advair 100/50mcg;   Drug: Advair 250/50mcg;   Drug: FLOVENT 100mcg;   Drug: FLOVENT 250mcg
Outcome Measures: Time to first event in the composite endpoint of serious asthma-related outcomes (asthma-related hospitalizations, endotracheal intubations, or deaths) over the 6-month study treatment period;   Time to first asthma exacerbation;   The number and percent of subjects experiencing asthma-related deaths;   The number and percent of subjects experiencing asthma-related endotracheal intubations;   The number and percent of subjects experiencing asthma-related hospitalizations;   The number of withdrawals from study treatment due to asthma exacerbation;   The number and percent of rescue-free days (days without use of rescue albuterol/salbutamol [other than pre-exercise treatment]);   The number and percent of asthma control days
5 Unknown  A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma
Condition: Asthma
Intervention: Drug: Mometasone or Advair
Outcome Measure:
6 Unknown  Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Advair;   Drug: Flovent
Outcome Measures: Change in serum C-reactive protein levels over 3 months between treatment groups.;   changes in serum interleukin levels; quality of life; FEV1 between treatment groups
7 Recruiting SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.
Condition: Asthma
Interventions: Drug: Advair 100/50mcg;   Drug: Advair 250/50mcg;   Drug: Advair 500/50mcg;   Drug: FLOVENT 100mcg;   Drug: FLOVENT 250mcg;   Drug: FLOVENT 500mcg
Outcome Measures: Time to first event in the composite endpoint of serious asthma related events (i.e. asthma-related hospitalization, asthma-related endotracheal intubation, or asthma-related death) over the 6-month treatment period;   Time to first severe asthma exacerbation;   Number and percent of subjects experiencing asthma related hospitalization;   Number and percent of subjects experiencing asthma related endotracheal intubation;   Number and percent of subjects experiencing asthma related endotracheal death;   The number of withdrawals from study treatment due to asthma exacerbation;   The number and percent of rescue-free days (days without use of rescue albuterol/salbutamol (other than pre-exercise)
8 Recruiting Best African American Response to Asthma Drugs
Condition: Asthma
Interventions: Drug: Flovent Diskus® 100 mcg;   Drug: Flovent Diskus® 250 mcg;   Drug: Flovent Diskus® 500 mcg;   Drug: Advair Diskus® 100/50 mcg;   Drug: Advair Diskus® 250/50 mcg
Outcome Measure: The primary outcome is a composite measure that uses exacerbations, asthma control days during the last 12 of 14 weeks of a treatment regimen, and percent predicted FEV1 at the end of a treatment regimen.
9 Recruiting Sub-Sensitivity to Long-Acting Bronchodilators (LABA)
Condition: Asthma
Interventions: Drug: fluticasone propionate and salmeterol;   Drug: budesonide and formoterol
Outcome Measures: Improvement in PC20;   Changes in FEV1
10 Recruiting Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Condition: Asthma
Intervention: Drug: budesonide/formoterol or fluticasone/salmeterol
Outcome Measures: Exhaled nitric oxide;   site/mechanism(s)airflow limitation;   dynamic hyperinflation
11 Unknown  Impact of Asthma Treatments on Daily Activities
Conditions: Asthma;   Allergies
Intervention:
Outcome Measure:
12 Recruiting Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
Condition: Asthma
Interventions: Drug: budesonide/formoterol;   Drug: fluticasone/salmeterol;   Drug: mometasone/formoterol;   Drug: Prednisone
Outcome Measures: use exhaled nitric oxide as a surrogate marker of large airway vs small airway/lung inflammation following various doses of inhaled corticosteroids;   determine site of airflow limitation, whether predominantly large and /or small airways using expiratory flow volume curves obtained before and after asthmatics breathe a 80% helium-20% oxygen gas mixture;   investigate the mechanisms that limit expiratory airflow: intrinsic airway obstruction vs loss of lung elastic recoil;   dynamic hyperinflation;   Evaluate large and small airways and lung parenchyma in autopsied asthmatics and look for unsuspected emphysema;   Optical Coherence Tomography
13 Recruiting Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Aclidinium Bromide / Formoterol Fumarate;   Drug: Salmeterol / Fluticasone
Outcome Measures: Peak forced expiratory volume in one second (FEV1) at week 24;   Transition Dyspnoea Index (TDI) focal score at week 24
14 Recruiting Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated COPD Patients
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: salmeterol/fluticasone;   Drug: ipatropium/salbutamol;   Drug: Methylprednisolone;   Drug: Additional broncho-dilators inhalation;   Other: Determining personal target airway resistance;   Device: Ventilator support
Outcome Measures: ∆Raw (the difference between measured and target airway resistance);   Rapidity of ∆Raw change;   number of ventilator-free days from day 1 to 28;   Percentage of breathing without assistance by day 28;   number of episode of nosocomial pneumonia;   Number of total puff of rescue short-acting bronchodilator;   number of drug-related adverse effect;   Mortality rate
15 Recruiting Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program
Conditions: Lung Diseases;   Medication Compliance
Interventions: Drug: Fluticasone propionate 500mcg/salmeterol 50mcg;   Behavioral: Medication Adherence Counseling
Outcome Measures: Change in measures of airflow and lung volumes by spirometry and small airway dysfunction by impulse oscillometry and association with uncontrolled lower respiratory symptoms;   Change in lower respiratory symptom control status;   Bronchial Hyperresponsiveness;   Inflammatory Markers Associated with Airway Disease (CRP, RAST, Eos and Periostin);   Gastroesophageal reflux symptoms;   Chronic rhinosinusitis symptoms;   Paradoxical vocal cord motion (PCVM);   Changes in levels of fractional exhaled nitric oxide (FeNO)
16 Not yet recruiting Long-Term Safety Evaluation of Dupilumab in Patients With Asthma
Condition: Asthma
Interventions: Drug: dupilumab SAR231893 (REGN668);   Drug: fluticasone propionate and salmeterol;   Drug: budesonide and formoterol;   Drug: mometasone furoate and formoterol
Outcome Measures: Number of participants with adverse events;   Assessment of safety parameters (laboratory data, electrocardiogram and vital signs) - clinically significant changes from baseline;   Forced expiratory volume in one second - clinically significant changes from baseline;   Asthma control questionnaire - clinically significant changes from baseline;   Asthma symptom scores - clinically significant changes from baseline;   Asthma Quality of Life Questionnaire (AQLQS) - clinically significant changes from baseline;   Anti-drug antibodies - changes from baseline;   Biomarkers - changes from baseline
17 Recruiting A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial
Condition: Asthma
Interventions: Drug: fluticasone and salmeterol;   Drug: Leukotriene receptor antagonist;   Drug: Theophylline;   Drug: Tiotropium
Outcome Measures: Asthma Control Test;   The Asthma Symptom Utility Index(AUSI);   Physiologic Measures
18 Recruiting Long-acting Beta Agonist Step Down Study
Condition: Asthma
Interventions: Drug: Fluticasone/Salmeterol Diskus;   Drug: Fluticasone Diskus
Outcome Measures: Treatment Failure;   Pulmonary Function;   Rate of episodes of poor asthma control

These studies may lead to new treatments and are adding insight into Advair etiology and treatment.

A major focus of Advair research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Advair